CM
Therapeutic Areas
Oculis Holding AG Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCS-01 | Diabetic Macular Edema (DME) | Phase 3 |
| OCS-02 (licaminlimab) | Dry Eye Disease (DED) | Phase 2b/3 |
| OCS-05 | Acute Optic Neuritis (AON) | Phase 1 |
Leadership Team at Oculis Holding AG
RS
Riad Sherif, M.D.
Chief Executive Officer and Director
RM
R. Michael Gendreau, M.D., Ph.D.
Chief Medical Officer
SC
Sylvia Cheung, CPA
Chief Financial Officer
PF
Patricia F. Walker, M.D., Ph.D.
Chief Scientific Officer
DH
David H. Moore, J.D.
Chief Legal Officer and Corporate Secretary
CA
Christina Ackermann
Chief Operating Officer
ED
Eric D. Donnenfeld, M.D.
Chairman of the Board
AY
Anthony Y. Sun, M.D.
Director
LS
Laurie Smaldone Alsup, M.D.
Director
GO
Geraldine O'Keeffe
Director